Figure 4.
![PML::RARA detection by RAPID-CRISPR assay using RT-LAMP to expedite the turnaround time of APL diagnosis. (A) Optimization of RT-LAMP using PB of 2 healthy individuals (H1 and H2) served as a control (no template control [NTC]). (B) Quantification of fluorescence of GUSβ by RAPID-CRISPR assay using 1-step RT-LAMP in control samples. (C) Quantification of fluorescence of PML::RARA by RAPID-CRISPR assay using RT-LAMP in APL cases (n = 8) and control (n = 5). The results are represented as a mean ± standard deviation; P < .0001. (D) LF-based readouts of 4 APL cases and 4 controls by RAPID-CRISPR assay using RT-LAMP.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/9/3/10.1182_bloodadvances.2024014539/2/blooda_adv-2024-014539-gr4.jpeg?Expires=1743218225&Signature=kCaYxXbb162aRya-CYI8I8Z96JFaGyJUSg9PtNWt1WtkvlSaBVoTnN-Z3X6zq9Rbzh6Bu97sEZe5w9vRQuPlRZCJukpmCW~iEd7UdKwCXqFALs11vgcEyCGM41YGtC0E13I1j2BTFmTJPM1wRlZhKQscvgstkkXkwlS4LFo2DpT1O12t9xzFL7ilofmWqjTQagpRSHS8pLlyD~vP0re3vmSO5~PuOnxUR2q~8yiqIFwBnO3SYwM2gPpfUR5UICDJ2ScQmABWffe9AHrPjGSmRr9HpildNwUwNweEYrp6ZmmpxTzkqSathqNYI3ENjA5Q2yhQIBAl4pkrZgHlSj~QPQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
PML::RARA detection by RAPID-CRISPR assay using RT-LAMP to expedite the turnaround time of APL diagnosis. (A) Optimization of RT-LAMP using PB of 2 healthy individuals (H1 and H2) served as a control (no template control [NTC]). (B) Quantification of fluorescence of GUSβ by RAPID-CRISPR assay using 1-step RT-LAMP in control samples. (C) Quantification of fluorescence of PML::RARA by RAPID-CRISPR assay using RT-LAMP in APL cases (n = 8) and control (n = 5). The results are represented as a mean ± standard deviation; P < .0001. (D) LF-based readouts of 4 APL cases and 4 controls by RAPID-CRISPR assay using RT-LAMP.
